Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for XGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -0.543M
March 31, 2026 -0.228M
December 31, 2025 -0.035M
September 30, 2025 -0.275M
June 30, 2025 -0.209M
March 31, 2025 -0.107M
December 31, 2024 -0.146M
September 30, 2024 -0.147M
June 30, 2024 -0.136M
March 31, 2024 -0.086M
December 31, 2023 -0.084M
September 30, 2023 -0.002M
June 30, 2023 -0.322M
March 31, 2023 -0.396M
December 31, 2022 -0.406M
September 30, 2022 -0.879M
June 30, 2022 -1.946M
March 31, 2022 -1.087M
December 31, 2021 -1.064M
September 30, 2021 -0.475M
June 30, 2021 -0.714M
March 31, 2021 -0.167M
December 31, 2020 -0.005M
September 30, 2020 -0.213M
June 30, 2020 -0.153M
Date Value
March 31, 2020 -0.084M
December 31, 2019 -0.026M
September 30, 2019 -0.002M
June 30, 2019 0.288M
March 31, 2019 -0.363M
December 31, 2018 0.929M
September 30, 2018 0.94M
June 30, 2018 -0.016M
March 31, 2018 -2.052M
December 31, 2017
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
December 31, 2015 -0.159M
September 30, 2015 -0.244M
June 30, 2015 -0.389M
March 31, 2015 -0.008M
December 31, 2014 -0.043M
September 30, 2014 -0.181M
June 30, 2014 -0.38M
March 31, 2014 -0.045M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. -3.20M
BioRestorative Therapies, Inc. 0.9684M
CareDx, Inc. 280.59M
Natera, Inc. -63.43M
Sera Prognostics, Inc. 6.394M